Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 4/20 | 0.56 |
| ▸ | TACR1 | P25103 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 4/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CCKBR | P32239 | 4/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13138388 | 0.90 | TACR1 (0.62) | RENTACR1CTSLCTSSCTSK | |
| SCHEMBL13138425 | 0.87 | REN (0.53) | RENTACR1CTSLCTSSCTSK | |
| SCHEMBL13163790 | 0.86 | REN (0.51) | RENTACR1CTSLCTSSCTSK | |
| SCHEMBL13138423 | 0.86 | REN (0.55) | RENTACR1CTSLCTSSCTSK | |
| SCHEMBL12555965 | 0.86 | TACR1 (0.67) | RENTACR1CTSLCTSSCTSK | |
| SCHEMBL29419173 | 0.86 | TACR1 (0.67) | RENTACR1CTSLCTSSCTSK | |
| SCHEMBL13138384 | 0.85 | TACR1 (0.63) | RENTACR1CTSLCTSSCTSK | |
| SCHEMBL13138421 | 0.85 | TACR1 (0.63) | RENTACR1CTSLCTSSCTSK | |
| SCHEMBL13138392 | 0.84 | REN (0.54) | RENTACR1CTSLCTSSCTSK | |
| SCHEMBL5424818 | 0.84 | REN (0.51) | RENTACR1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222549-A1 | DECHALCOGENATIVE METHODS FOR THE PREPARATION OF ALLYLIC SULFIDES | NIH-DEITR | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222549-A1 | DECHALCOGENATIVE METHODS FOR THE PREPARATION OF ALLYLIC SULFIDES | TST, SCLY, AP2S1 | REN 3877/4885TACR1 816/4885CTSL 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.